CereScan Participates in Largest Brain Amyloid Scan Research Study

Alzheimer's IDEAS brain studyCereScan is now a registered amyloid positron emission tomography (PET) imaging site in the $100 million Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Ideas-Study.org). CereScan can offer Medicare-covered amyloid PET scans to study eligible Medicare patients who are referred by participating IDEAS dementia specialists (neurologists, psychiatrists and geriatric medicine physicians). The research study seeks to determine the clinical usefulness of PET imaging of brain amyloid deposits in the diagnosis of patients who are being evaluated for Alzheimer’s disease and dementia.

“Medicare will only cover these exams for seniors if done as part of clinical trial or data registry. Currently no private insurer covers amyloid PET scans for patients being evaluated for dementia or memory loss. I encourage local dementia specialists to review participation requirements, register for the trial and refer eligible patients to CereScan to get Medicare-covered amyloid PET scans that may better inform their care and future Alzheimer’s diagnosis and treatment,” said John Kelley, CereScan Chairman and Chief Executive Officer.

Diagnosing Alzheimer’s Disease is Complex

With no single test currently available, diagnosis is based on an individual’s history, physical examination and cognitive testing. Amyloid PET imaging represents a potential major advance in the assessment of people with cognitive impairment. The scan visualizes plaques present in the brain that are prime suspects in damaging and killing nerve cells in Alzheimer’s. Before amyloid PET, these plaques could only be detected by examining the brain at autopsy. The IDEAS study will follow Medicare beneficiaries to determine if amyloid PET scans may help physicians make more informed treatment decisions.

“There has never been a study of this scale to evaluate the clinical value of brain amyloid imaging in diagnosing and caring for those affected by Alzheimer’s. The dementia specialists and facilities that register for the IDEAS Study will play an essential role in engaging the nearly 19,000 individuals needed in the study and carrying out the amyloid PET scans,” said Maria Carrillo, PhD, Alzheimer’s Association chief science officer and IDEAS Study investigator.

How to Participate in the IDEAS Study

Patients cannot directly enroll in the IDEAS Study. IDEAS Study dementia specialists must enroll patients whose cases meet the study criteria and refer them to registered PET imaging facilities, such as CereScan for an amyloid PET scan. These scans will be performed and interpreted by a nuclear medicine physician or radiologist who is registered to take part in the IDEAS Study. Results will be provided to the ordering doctor for disclosure to the patient and to support further diagnostic decisions. Scan results and diagnosis will be captured for the study.

The IDEAS Study is sponsored by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN), with funding and direction provided by the Alzheimer’s Association, the ACR and the manufacturers of the FDA-approved radiopharmaceuticals for amyloid imaging.

Step-by-step registration instructions are available for board-certified neurologists, psychiatrists and geriatric medicine physicians interested in enrolling eligible patients in the IDEAS Study.

Registered dementia specialists interested in referring enrolled patients to CereScan can call (866) 722-4806 or write to sstrauss@cerescan.com.

NCH in Metro Chicago Joins CereScan Family to Help Patients with Head and Chronic Brain Injuries

CereScan Functional Brain Imaging and NCH

CereScan® has increased its functional brain imaging diagnostics network with the addition of Northwest Community Healthcare (NCH) in Arlington Heights. Patients in the Midwest region who are suffering from lingering head and brain injuries may now use the nation’s leading provider of statistically measured brain diagnostics to understand the biological basis of their symptoms for a more direct path to treatment and recovery.

“We’re honored to partner with a nationally recognized provider with some of the top Radiologists in the Great Lakes region at Northwest Community Healthcare,” said John Kelley, CEO and chairman of CereScan. “Our alliance will allow CereScan’s functional brain diagnostic services to be available to patients and practitioners in the Midwest region.  We pursued a relationship with NCH because our values and philosophy about healthcare are closely aligned.”

CereScan Functional Brain ImagingHeadquartered in Denver, CereScan uses its patented process to combine patient-clinical information, functional brain imaging and advanced processing software to help medical providers and their patients find a more complete and accurate diagnosis. Through its agreement, NCH has integrated CereScan’s patented process, using qSPECT (quantitative Single Photon Emission Computed Tomography) imaging data to assist referring physicians in the evaluation of complex neurological conditions.

“CereScan values the practice philosophy of NCH. Both parties believe that every person is unique and so is their diagnosis and treatment,” said neurosurgeon Shaun T. O’Leary, M.D., Ph.D., FAANS. “Through the clinical data, the innovations and the imaging software available through CereScan, we have a plethora of resources to make NCH an even higher-quality institution for brain disorders.”

Dr. O’Leary joined NCH’s Medical Group in December 2014 and is helping lead the hospital’s growth of neurosurgical patient care. NCH is the only hospital in Illinois to receive the 2017 Healthgrades® Neurosciences, Stroke Care and Cranial Neurosurgery Excellence Award. NCH was named one of America’s 100 Best Hospitals for Stroke Care for its performance in 34 of the most common inpatient procedures and conditions, as defined by Healthgrades, which evaluated nearly 4,500 hospitals across the country.

Headed by Dr. O’Leary, NCH’s Neuroscience Center will provide patients with full-service care for brain injuries. The NCH Neuroscience Center specializes in treating complex neurological conditions affecting the brain, nerves and spinal cord.

To make an appointment with Dr. O’Leary, please fill out our Contact Us form or call (866) 722-4806.

About Northwest Community Healthcare (NCH)
Serving Chicago’s northwest suburbs since 1959, NCH is a comprehensive, patient-centered system of care that serves more than 350,000 outpatients each year and more than 20,000 inpatients treated annually at the 489-bed acute care hospital in Arlington Heights. The award-winning hospital holds the prestigious Magnet designation for nursing excellence, is designated as a Primary Stroke Center, and earned the Joint Commission’s Gold Seal of Approval in 2015.  NCH has four Immediate Care locations in the northwest suburbs. NCH has a medical staff of more than 1,000 physicians, which includes the board-certified primary care doctors and specialists of the NCH Medical Group. These physicians have selected our facility as a place where they want to treat and care for their private patients. For more information, or to find a doctor on the NCH Medical staff, visit www.nch.org.

 

CereScan’s Ability to Accurately Show Presence of Mild to Moderate Traumatic Brain Injuries Provides Value in Legal Process

While traditional approaches to traumatic brain injury detection can be inconclusive, including MRI and CT scans, another technology is gaining notoriety with legal and medical professionals.

MRI vs CereSCanReferred by the Centers for Disease Control and Prevention as a “silent epidemic,” traumatic brain injury (TBI) affects millions every year, but this invisible injury is often difficult to diagnose.  Traditional imaging results are generally inconclusive for people with concussions – or mild TBI – as the damage associated with the injury often impacts cellular function and MRI and CT scans only analyze the structure of the brain.

However, an advance technology utilized by CereLaw called qSPECT (quantitative Single Photon Emission Computed Tomography) is aiding attorneys and medical providers.  The qSPECT process establishes the existence of mild- to moderate-TBI and its effects through SPECT imaging, advanced imaging software, detailed medical history and clinical assessments. SPECT imaging measures and analyzes blood flow levels throughout the brain to pinpoint the exact area impacted by the injury.

Lead by Brett Green, Esq. the CereLaw team is increasing awareness of TBI detection technologies available to attorneys through industry conferences such as the 2016 BIACAL Med-Legal Conference on Nov. 18 – 19 in Napa, California, and the Texas Trial Lawyers Association’s Annual Meeting on Dec. 8 – 9 in Dallas, Texas.

“Industry conferences are a great way for us to increase education around some of the advanced diagnostic tools for brain injuries that can help correlate or distinguish brain-based disorders,” said Brett Green, vice president of CereLaw. “We also had the opportunity to meet with experts from various market segments and share best practices. The experiences and key learnings were invaluable.”

CereLaw is a division of CereScan, a functional brain diagnostics and data analytics company. The company has been involved in over 300 legal cases and has developed an unmatched success rate from cases in more than 30 states. With over 25 years of experience with brain injuries, CereScan’s team provides unparalleled expertise and support not found at other brain imaging facilities.

“The technology and team at CereScan has become a critical component to our TBI practice,” said Ronald W. Armstrong II, attorney at The Armstrong Firm, PLLC, San Antonio, Texas.  “Additionally, the quality of the results and professionalism exhibited by them is second to none.”

For more information about CereLaw’s brain forensic services please contact Brett Green at bgreen@cerescan.com or Lisa Teitelman at lteitelman@cerescan.com or call toll free at  (855) 838-2241. Connect with CereLaw on Twitter @CereLaw or online at https://www.cerelaw.com.

CereScan Poised to Change Brain Diagnostics as it Expands into Alabama

 

CereScan®’s functional brain imaging and analytical services are now available at the Helen Keller Hospital’s Imaging Center in Sheffield, Alabama. A Center-of-Excellence hospital, Helen Keller is strategically near major metropolitan areas, such as Nashville, Birmingham and Memphis and several military bases.

Read more